Skip to Content

'
Chantale Bernatchez, Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
7455 Fannin
Unit Number: 904
Houston, TX 77054
Room Number: 1SCR2.2018
Phone: 713-563-8830
Fax: 713-745-0131

Education & Training

Degree-Granting Education

2004 Laval University, Quebec, Canada, PHD, Immunology
1998 Laval University, Quebec, Canada, MSc, Immunology
1995 Universite du Quebec a Trois-Rivieres, Quebec, Canada, BS, Medical Biology

Postgraduate Training

1/2007-10/2008 Postdoctoral Fellow, Cancer Immunology, MD Anderson Cancer Center, Melanoma Oncology department, Houston, TX
1/2005-4/2005 Postdoctoral Fellow, Immunology, Laval University, Quebec, Canada

Experience/Service

Academic Appointments

Senior Research Scientist, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/2011-5/2013
Research Scientist, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2008-2/2011

Other Appointments/Responsibilities

Research Scientist, Bio-Quant Inc., San Diego, CA, 6/2005-6/2006

Selected Publications

Peer-Reviewed Original Research Articles

1. Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol 189(11):5476-84, 12/2012. e-Pub 10/2012. PMCID: PMC3504175.
2. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 12/2012. e-Pub 10/2012. PMCID: PMC3525747.
3. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18(19):5329-40, 10/2012. e-Pub 7/2012. PMCID: PMC3463754.
4. Zhang M, Maiti S, Bernatchez C, Huls H, Rabinovich B, Champlin RE, Vence LM, Hwu P, Radvanyi L, Cooper LJ. A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy. Clin Cancer Res 18(17):4733-42, 9/2012. e-Pub 7/2012. PMID: 22761473.
5. Haymaker C, Wu R, Bernatchez C, Radvanyi L. PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint. Oncoimmunology 1(5):735-738, 8/2012. PMCID: PMC3429577.
6. Bernatchez C, Radvanyi LG, Hwu P. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol 39(2):215-26, 4/2012. PMCID: PMC3500663.
7. Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 18(2):160-75, Mar-Apr, 3/2012. PMCID: PMC3315690.
8. Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, Wardell S, Bastian BC, Woodman SE. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res 25(2):182-7, 3/2012. e-Pub 2/2012. PMCID: PMC3288394.
9. Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, Fernandez-Vina M, Cano P, Cooper L, Abbruzzese J, Hwu P, Chang DZ, Radvanyi LG. Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine 29(16):3021-30, 4/2011. e-Pub 2/2011. PMCID: PMC3070784.
10. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 34(3):236-50, 4/2011. PMCID: PMC3063939.
11. Boilard E, Bourgoin SG, Bernatchez C, Surette ME. Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood 102(8):2901-9, 10/2003. e-Pub 6/2003. PMID: 12829607.
12. Boilard E, Bourgoin SG, Bernatchez C, Poubelle PE, Surette ME. Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans. FASEB J 17(9):1068-80, 6/2003. PMID: 12773489.
13. Surette ME, Fonteh AN, Bernatchez C, Chilton FH. Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells. Carcinogenesis 20:757-763, 1999.
14. Leblanc E, Papadopoulou B, Bernatchez C, Quellette M. Residues involved in co-factor and substrate binding of the short-chain dehydrogenase/reductase PTR1 producing methotrexate resistance in Leishmania. Eur J Biochem 251:768-774, 1998.
15. Bernatchez C, Al-Daccak R, Mayer PE, Mehindate K, Rink L, Mecheri S, Mourad W. Functional analysis of Mycoplasma arthritidis-derived mitogen interactions with class ll molecules. Infect Immun 65:2000-2005, 1997.

Invited Articles

1. Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the Development of Cancer Immunotherapies. Trends Immunol 34(2):90-8, 2/2013. e-Pub 9/30/2012. PMCID: PMC3565019.
2. Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi L. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 18:160-175, 2012.
3. Bernatchez C, Radvanyi L, Hwu P. Advances in the treatment of metastatic melanoma: adoptive T-cell therpay. Semin Oncol 39:215-226, 2012.

Abstracts

1. Radvanyi L, R., C. Bernatchez, M. Zhang, P. Miller, M. Glass, R.Bassett, J. D. McMannis, E. Shpall, V. Prieto, N. Papadopoulos, and P. Hwu. Adoptive T-cell Therapy for Metastatic Melanoma: The MD Anderson Experience. International Society for Biological Therapy of Cancer (iSBTc) 25th Annual Meeting, Washington D.C. and NIH campus, Bethesda, MD,, September 30 - October 4, 2010.
2. Bernatchez, C., Y. Li, C.G. Loannides, M. Fernandez-Vina, P. Cano, D.Z. Chang and L. Radvanyi. New epitopes to improve peptide vaccination against the tumor-associated antigen Survivin., Experimental Biology 2008, San Diego, CA,, April 5-9, 2008.
3. Bernatchez, C., S.G. Bourgoin et M.E. Surette. Patron d'activation des membres de la famille RSK (ribosomal S6 kinases) lors d'une stimulation du recepteur des cellules T (TCR), 43rd annual reunion of Club de Recherches Cliniques du Quebec, Mont Ste-Anne (Quebec, Canada),, September 20-22, 2001.
4. Bernatchez, C., S. G. Bourgoin and M.E. Surette. Pattern of activation of human of Rsk family members upon T cell receptor stimulation, Experimental Biology 2001, Orlando, Florida,, March 31st - April4th, 2001.
5. Surette, M.E., C. Bernatchez and P. Borgeat. Autocrine activation of human PMN by LTB4 in the synthesis of 5-LO products from exogenous arachidonic acid: inhibition by adenosine A2 receptor agonists, Experimental Biology'99, Washington, D.C.,, April 17-21, 1999.
6. Bernatchez C., P. Borgeat and M.E. Surette. L'acide arachidonique exogene induit une forte synthese de leucotrienes par le neutrophile humain, ACFAS meeting, Quebec, Canada,, May, 1998.
7. Haymaker, Cara; Chen, Jie Qing; Bernacthez, Chantale; Kale, Charuta; Torres-Cabala, Carlos; Radvanyi, Laszlo. Usurpation of a lymphocyte costimulatory molecule as a novel Melanoma cell survival pathway. American Association of Immunologists, Bethesda, MD 190, May 3-7, 2013.
8. Haymaker, Cara; Wu, Richard; Bernatchez, Chantale; Hwu, Patrick; Radvanyi, Laszlo. BTLA: new biomarker for a highly proliferative CD8+TIL subset associated with Melanoma regression during adoptive cell therapy. American Association of Immunologists, Bethesda, MD 190, May 3-7, 2013.

Last updated: 6/9/2014